Summary by Moomoo AI
Kehi Pharmaceutical Co., Ltd. announced its interim performance for the period ending June 30, 2024, showing unaudited comprehensive interim performance and comparative figures for the same period in 2023. The company has made progress in technology innovation, product pipeline, and business operations in the United States and China. SaiKeze® has been approved by the National Medical Products Administration for marketing and is used to treat relapsed or refractory multiple myeloma in adult patients. The company has signed a cooperation agreement with Huadong Medicine to commercialize SaiKeze® in mainland China. As of July 31, 2024, SaiKeze® has been included in the insurance plans of nearly 20 provinces or cities and has received 52 orders. Other products of the company, such as Shuiruijiaolunsi injection and CT071, are also undergoing clinical trials. The company's revenue is approximately RMB 6 million, mainly from SaiKeze®, with a gross profit of approximately RMB 2 million and a net loss of approximately RMB 352 million, a decrease of approximately RMB 52 million compared to the same period last year. The cash and bank balance is approximately RMB 1,653 million.
